|
|
|
|
Curr Drug Saf 2010,Apr,01;5(2):132-48; (PMID: 19814703)
[...]midazolam, and lidocaine), and antiserotonins (ondansetron, granisetron, tropisetron, dolasetron, and ramosetron). Antiserotonins are more effective than traditional antiemetics, but these drugs are not entirely effective, perhaps because most of them act through the blockade on one type of receptor.[...]
|
|
|
J Spinal Disord Tech 2010,Apr,01;23(2):139-45; (PMID: 20375829)
[...]The new regimen included preoperative and postoperative scheduled extended-release oxycodone, gabapentin, and acetaminophen, intraoperative dolasetron and as-needed postoperative short-acting oral oxycodone. Patient surveys and chart audits were used to measure [...]
|
|
|
Expert Rev Anticancer Ther 2010,Feb,01;10(2):137-48; (PMID: 20131990)
[...] and compare the efficacy and tolerability with the other 5-HT(3) receptor antagonists, ondansetron, granisetron and dolasetron.
|
|
|
Paediatr Drugs 2010,Jan,01;12(1):51-61; (PMID: 20034341)
[...]Possible barriers to adherence to the pediatric antiemetic selection guidelines that are currently available are discussed, and published pediatric experience with antiemetic agents recommended in the current adult antiemetic selection guidelines (dolasetron, tropisetron, palonosetron, aprepitant) is summarized in this review. The use of novel and emerging antiemetic therapeutic interventions [...]
|
|
|
Curr Drug Saf 2010,Jan,01;5(1):105-11; (PMID: 20210727)
[...]It's very important take in account the synergic effects over the QT prolongation when effective antiemetics like 5-HT3 receptor antagonist (granisetron, ondansetron, and dolasetron) are administered. The Knowledge of their pharmacological properties is of vital importance to avoid exposing particularly vulnerable individuals as those with [...]
|
|
|
Drugs 2009,Nov,12;69(16):2257-78; (PMID: 19852528)
[...]palonosetron was noninferior to intravenous ondansetron (with statistically greater efficacy than ondansetron) or dolasetron in preventing CINV following MEC, or to intravenous ondansetron or granisetron in preventing CINV following HEC, in the acute phase.[...]
|
|
|
Support Care Cancer 2009,Sep,01;17(9):1187-93; (PMID: 19205754) [FULL TEXT AVAILABLE]
[...]vomiting, on the pharmacokinetics of the commonly prescribed 5-hydroxytryptamine receptor 3 receptor antagonists, dolasetron or granisetron. MATERIALS AND METHODS: In a phase I, open-label, two-part, two-period, single-sequence study, two cohorts of healthy subjects received either oral [...]
|
|
|
Curr Cardiol Rev 2009,Aug,01;5(3):166-76; (PMID: 20676275) [FULL TEXT AVAILABLE]
[...]Some examples are dofetilide, quinidine, sotalol, erythromycin, grepafloxacin, cisapride, dolasetron, thioridazine, haloperidol, droperidol and pimozide. Other drugs achieve channel inhibition indirectly by impairing channel traffic from the [...]
|
|
|
Lancet Oncol 2009,Feb,01;10(2):115-24; (PMID: 19135415)
[...] is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to [...]
|
|
|
Curr Drug Saf 2009,Jan,01;4(1):62-73; (PMID: 19149526)
[...], and midazolam. Serotonin receptor antagonists, which include ondansetron, granisetron, tropisetron, dolasetron, and ramosetron, are more effective than traditional antiemetics. However, these drugs are not entirely effective, perhaps because most of them act through the blockade on one type of receptor.[...]
|
 1 2 3 4 5 6 7 8 
|
|
